Search results
Results From The WOW.Com Content Network
Anticoagulants are not routinely recommended for people with heterozygous factor V Leiden, unless there are additional risk factors present, but are given when such an event occurs. [ 13 ] [ 14 ] [ 15 ] A single occurrence of deep vein thrombosis or pulmonary embolism in people with factor V Leiden warrants temporary anticoagulant treatment ...
However, people with homozygous factor V Leiden, and people with heterozygous factor V Leiden who have an additional thrombophilic condition (e.g., antithrombin deficiency, protein C deficiency, or protein S deficiency), should be considered for lifelong oral anticoagulation therapy. [17]
[1] [5] This ratio is inversely related to the degree of APC resistance. [7] The ETP-based APC resistance test involves the addition of APC to a thrombin generation assay (TGA). [5] This results in an inhibition of thrombin generation as measured by reduction of the endogenous thrombin potential (ETP; area under the thrombin generation curve). [5]
14067 Ensembl ENSG00000198734 ENSMUSG00000026579 UniProt P12259 O88783 RefSeq (mRNA) NM_000130 NM_007976 RefSeq (protein) NP_000121 NP_032002 Location (UCSC) Chr 1: 169.51 – 169.59 Mb Chr 1: 163.98 – 164.05 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Coagulation factor V (Factor V), also less commonly known as proaccelerin or labile factor, is a protein involved in ...
In fact, Factor V Leiden is the most common cause of inherited thrombosis. [26] Heterozygous factor V Leiden is present in approximately 5% of the white population in the United States and homozygous factor V Leiden is found less than 1% of this population. [27]
A 2005 article concluded that heterozygous carriers who take combined birth control pills are at a 15-fold increased risk of venous thromboembolism, [12] while carriers also heterozygous with factor V Leiden have an approximate 20-fold higher risk. [2]
The minor ("type 2") thrombophilias are much more common. Factor V Leiden is present in 5% of the population of Northern European descent, but much rarer in those of Asian or African extraction. In people with thrombosis, 10% have factor V Leiden. In those who are referred for thrombophilia testing, 30–50% have the defect.
Factor V Leiden and mutations of the prothrombin gene are the two most common genetic causes of hypercoagulability. About 5% of the general population have these heterozygous mutations and in the thrombophilic population, 45–63% have these mutations. [6]